Edition:
United Kingdom

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

37.28USD
16 Nov 2018
Change (% chg)

$1.43 (+3.99%)
Prev Close
$35.85
Open
$35.42
Day's High
$37.59
Day's Low
$35.42
Volume
244,532
Avg. Vol
149,454
52-wk High
$54.45
52-wk Low
$13.25

Latest Key Developments (Source: Significant Developments)

Atara Biotherapeutics Reports Q2 Loss Per Share Of $1.15
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q2 LOSS PER SHARE $1.15.Q2 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.  Full Article

Atara Biotherapeutics Appoints Utpal Koppikar As Chief Financial Officer
Thursday, 7 Jun 2018 

June 7 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES APPOINTMENT OF UTPAL KOPPIKAR AS CHIEF FINANCIAL OFFICER.ATARA BIOTHERAPEUTICS INC - UTPAL KOPPIKAR HAS JOINED ATARA AS CHIEF FINANCIAL OFFICER, EFFECTIVE IMMEDIATELY.  Full Article

Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS.ATARA BIOTHERAPEUTICS INC - FIRST RESULTS FROM ATA188 PHASE 1 STUDY IN PATIENTS WITH PROGRESSIVE MS IN FIRST HALF OF 2019.  Full Article

Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics
Friday, 5 Jan 2018 

Jan 5 (Reuters) - CAMBER CAPITAL MANAGEMENT LLC ::CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING.  Full Article

Atara Biotherapeutics prices public offering of 7 mln shares at $18.25 per share
Thursday, 4 Jan 2018 

Jan 3 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.00 MILLION COMMON SHARES PRICED AT $18.25PER SHARE.  Full Article

Atara Biotherapeutics Announces Proposed Offering Of Common Stock
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS INC - ‍COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF ITS SHARES OF COMMON STOCK​.  Full Article

Atara Biotherapeutics Gets FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE TWO PHASE 3 CLINICAL STUDIES TO EVALUATE TABELECLEUCEL IN PATIENTS WITH RITUXIMAB-REFRACTORY EPSTEIN-BARR VIRUS ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+PTLD).ATARA BIOTHERAPEUTICS- RESULTS FROM FIRST TABELECLEUCEL PHASE 3 STUDY TO REACH PRIMARY ENDPOINT ARE EXPECTED TO BE ANNOUNCED IN FIRST HALF OF 2019.ATARA-‍PLANS TO SUBMIT TABELECLEUCEL CMA APPLICATION IN EU FOR PATIENTS WITH RITUXIMAB-REFRACTORY EBV+PTLD POST HEMATOPOIETIC CELL TRANSPLANT IN H1 2019.  Full Article

Morgan Stanley Reports 5 Pct Passive Stake In Atara Biotherapeutics As Of Nov 27
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Atara Biotherapeutics Inc ::MORGAN STANLEY REPORTS 5.0 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING.  Full Article

Atara Biotherapeutics reports Q3 loss per share $1.02
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Atara Biotherapeutics Inc :Atara Biotherapeutics Inc announces third quarter 2017 financial results and recent highlights.Q3 loss per share $1.02.Q3 earnings per share view $-0.98 -- Thomson Reuters I/B/E/S.Atara Biotherapeutics Inc - ‍cash, cash equivalents and short-term investments as of Sept 30, 2017 totaled $200.2 million.Atara Biotherapeutics Inc - ‍cash, cash equivalents and short-term investments will be sufficient to fund planned operations into Q1 2019​.  Full Article

Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Atara Biotherapeutics Inc :Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations, including updated interim results from a phase 1 study of autologous ATA190 in patients with progressive multiple sclerosis (MS).Atara Biotherapeutics Inc - ‍no significant adverse events have been observed in study​.  Full Article